Author:
Zhang Qin-Qin,An Xuan,Liu Ying-Hong,Li Shi-Ying,Zhong Qing,Wang Jing,Hu Huai-Dong,Zhang Da-Zhi,Ren Hong,Hu Peng
Abstract
Abstract
Background
The effect of antiviral therapy in chronic hepatitis B (CHB) on reducing the risk of long-term complications (LTCs) remains unclear so far. To study whether long-term nucleos(t)ide analogues therapy can reduce the risk of long-term complications.
Methods
We searched MEDLINE, EMBASE, OVID, the Cochrane Central Register of Controlled Trials. Relative risks (RRs) of long-term complications with or without treatment were studied. Also subgroup analyses including the status of drug-resistance, HBeAg and pre-existing compensated cirrhosis were done using relative risks of long-term complications either with or without treatment or among nucleos(t)ide analogues treatment groups.
Results
Six eligible studies (3644 patients in all) were included. Data showed the incidence of long-term complications in treatment groups was induced by 74%(RR:0.26, 95% CI: 0.15-0.47) compared with no treatment. Whether drug-resistant happened or not during the long-term therapy, the incidence of long-term complications was still significantly induced respectively by 45%(RR: 0.55,95%CI:0.40-0.76) and 78% (RR:0.22, 95%CI: 0.13-0.36). For both different status of HBeAg and pre-existing compensated cirrhosis, there was significant lower incidence of long-term complications in treatment groups compared with no treatment, too. Moreover, among the NA treatment groups, patients with drug-resistance had 2.64 times (RR:2.64, 95%CI: 1.58-4.41) higher chance of developing to long-term complications, and patients with pre-existing compensated cirrhosis also had 3.07 times (RR:3.07, 95%CI: 1.04-9.11) higher chance of developing to long-term complications.
Conclusions
Long-term nucleos(t)ide analogue therapy for adults with CHB prevents or delays the development of long-term complications including decompensated cirrhosis, CHB-related death or CHB-related HCC in patients with CHB. The patients who need take antiviral drugs should receive the antiviral therapy as soon as possible.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Virology
Reference42 articles.
1. Lee WM: HBV infection. N Engl J Med 1997, 337: 1733-1745. 10.1056/NEJM199712113372406
2. Hollinger FB, Liang TJ: Hepatitis B Virus. In Fields Virology. 4th edition. Edited by: Knipe DM, Howley PM. Philadelphia, Lippincott Williams & Wilkins; 2001:2971-3036.
3. Saoleas M, Lygidakis NJ, Manti C: Hepatitis B today. Hepatogastroenterology 2007, 54: 545-548.
4. Liaw YF, Tai DI, Chu CM, Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8: 493-6. 10.1002/hep.1840080310
5. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A: Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32: 294-8. 10.1136/gut.32.3.294
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献